Pacer Advisors Inc. Trims Position in DaVita Inc. $DVA

Pacer Advisors Inc. reduced its position in DaVita Inc. (NYSE:DVA) by 99.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,847 shares of the company’s stock after selling 624,942 shares during the period. Pacer Advisors Inc.’s holdings in DaVita were worth $438,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DVA. Invesco Ltd. boosted its holdings in shares of DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares during the last quarter. Morgan Stanley lifted its position in DaVita by 5.1% during the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after buying an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after buying an additional 636,191 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in DaVita by 5.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after buying an additional 56,336 shares during the last quarter. Finally, LSV Asset Management grew its holdings in DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after buying an additional 9,739 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DVA has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday. Barclays boosted their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and a consensus target price of $221.75.

DaVita Stock Performance

DVA opened at $178.25 on Wednesday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The firm has a 50 day moving average price of $218.11 and a 200 day moving average price of $178.10. The company has a market cap of $11.37 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 0.61 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the previous year, the company posted $2.95 earnings per share. DaVita’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.90% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.